The long and still uncertain journey of BRAF as a prognostic tool in patients with papillary thyroid cancer
- PMID: 31090813
- PMCID: PMC10522134
- DOI: 10.20945/2359-3997000000140
The long and still uncertain journey of BRAF as a prognostic tool in patients with papillary thyroid cancer
Conflict of interest statement
Disclosure: no potential conflict of interest relevant to this article was reported.
Comment on
-
Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules.Arch Endocrinol Metab. 2019 Mar-Apr;63(2):107-112. doi: 10.20945/2359-3997000000116. Epub 2019 Mar 21. Arch Endocrinol Metab. 2019. PMID: 30916166 Free PMC article.
-
Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series.Arch Endocrinol Metab. 2019 Mar-Apr;63(2):97-106. doi: 10.20945/2359-3997000000120. Epub 2019 Mar 21. Arch Endocrinol Metab. 2019. PMID: 30916170 Free PMC article.
References
-
- Romitti M, Ceolin L, Siqueira DR, Ferreira CV, Wajner SM, Maia AL. Signaling pathways in follicular cell-derived thyroid carcinomas (review). Int J Oncol. 2013;42(1):19-28. - PubMed
-
- Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials